Zymeworks rises after unveiling leadership changes

Zymeworks

12/01/2026 14:40

** Shares of drug developer Zymeworks ZYME.O rise 2.3% to $23.70

** Co says it has appointed investment industry veteran Brian Cherry to its board of directors

** Cherry previously served as managing partner at private equity firm Oak Hill Capital - ZYME

** Adds Dr. Sabeen Mekan to become Chief Medical Officer on February 1, replacing Dr. Jeff Smith

** Mark Hollywood promoted to EVP and COO; five new VPs named to strengthen leadership team - ZYME

** Says Chief Financial and Business Officer Leone Patterson and General Counsel Daniel Dex to exit in Q1

** CEO Kenneth Galbraith to serve as acting CFO until successor is appointed - ZYME

** As of last close, stock up ~80% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))